Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Artelo Biosciences (Nasdaq: ARTL) has initiated the Phase 2a segment of its Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at treating cancer-related anorexia and weight loss. The study will assess 40 patients, using a 3:1 ratio for ART27.13 versus placebo over 12 weeks. Following positive safety outcomes in Phase 1b, a dose of 650 micrograms will be administered. About 18 clinical sites across five countries will participate. ART27.13 targets cannabinoid receptors and has shown potential for increasing appetite without adverse central nervous system effects. The global market for addressing anorexia in cancer patients is estimated over $2 billion. The company hopes to complete patient enrollment by mid-2024.
Artelo Biosciences (Nasdaq: ARTL) reported significant developments for the fiscal year ending December 31, 2022, highlighting $17.5 million in cash and marketable securities available to support operations into the latter half of 2024. The CEO emphasized advances in their clinical trial for ART27.13, aimed at treating cancer-related anorexia, with enrollment completion of all cohorts and the next Phase 2a stage anticipated to start in April 2023. The company also noted a net loss of $10.1 million for the year and a strategic full pipeline development, including research on their lead fatty acid binding protein inhibitor.
Artelo Biosciences (NASDAQ:ARTL), a clinical-stage pharmaceutical company, will present at the MicroCap Rodeo's Third Annual Winter Wonderland Best Ideas Virtual Investor Conference from February 21-24, 2023. CEO Gregory D. Gorgas is scheduled to present on February 22 at 9:00 a.m. Eastern Time, with a live webcast available for replay. The conference highlights 37 companies recommended by qualified institutional investors, showcasing top investment ideas. Artelo is focused on developing therapies for conditions including cancer, pain, and neurological disorders. For more details or to schedule meetings, interested parties can contact the company.
Artelo Biosciences (ARTL) has completed enrollment in the final cohort of its Phase 1b Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at evaluating safety and efficacy in cancer patients experiencing anorexia. The highest permissible dose of 650 micrograms has been administered, with preliminary results indicating a well-tolerated safety profile and mild adverse reactions. The company anticipates progressing to the randomized Phase 2a stage to assess the drug's effectiveness, targeting a market projected to exceed $2 billion for cancer-related appetite loss treatments. Artelo expresses gratitude to participants and research teams for overcoming enrollment challenges.
Artelo Biosciences, a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the Sequire Biotechnology Conference on February 2, 2023, at 1:00 PM ET. The presentation will focus on the Company’s ongoing Cancer Appetite Recovery Study (CAReS). The biotechnology sector is projected to reach $727 billion by 2025, highlighting its growth potential. This event, hosted virtually, aims to connect public biotech companies with investors. Artelo is dedicated to developing innovative treatments targeting significant unmet needs related to cancer and other conditions. More details can be found at artelobio.com.
Artelo Biosciences (Nasdaq: ARTL) reported financial results for the quarter ending September 30, 2022, showing a net loss of approximately $2.3 million, or $0.82 per share, compared to a loss of $2.2 million or $1.37 per share for the same period in 2021. As of September 30, 2022, the company had $19.5 million in cash and investments, expected to support operations through mid-2024. Enrollment for the Phase 2a Cancer Appetite Recovery Study (CAReS) is set to begin near year-end, following positive Phase 1b results.
Artelo also highlighted promising non-clinical data for its FABP5 platform, indicating potential treatments for both pain and anxiety.